The early buzz at ASH 2018 was rightly about the ECOG trial that was presented on the last day as a late breaking abstract.
In my interview at the opening of the conference, Dr. Stilgenbauer discusses the practice changing significance of this study that proved that ibrutinib and rituximab was superior to FCR for both overall and progression free survival for frontline patients <70 years old..
For more see: cllsociety.org/2019/01/ash-...
This is real important.
This morning I was on the phone with CLL advocates from several different countries whose work is now to change the circumstances for those who live in the countries they serve and to help deal with the fallout until that happens.
Our work is increasingly to ensure knowledge about and access to the best care.
Stay strong. We are all in this together